World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
151058
World Ranking
2168
National Ranking
1227

Overview

Jeffrey A. Sosman is affiliated with Northwestern University in the United States. Their research predominantly lies in the field of Medicine, with significant contributions across multiple subfields such as Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology, and Cancer Research.

The scientist's work focuses on key topics including Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Renal cell carcinoma treatment, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, and Cancer Genomics and Diagnostics.

Frequent publication venues for their research include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Journal of the National Comprehensive Cancer Network
  • Regular and Young Investigator Award Abstracts
  • Cancer Research

Prominent co-authors collaborating with Jeffrey A. Sosman are:

  • Michael B. Atkins
  • Naomi B. Haas
  • Hans J. Hammers
  • David F. McDermott
  • Opeyemi A. Jegede

Selected recent papers authored or co-authored by Jeffrey A. Sosman illustrate the scope of their research and include:

  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events," 2021, Journal for ImmunoTherapy of Cancer
  • "Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma," 2023, New England Journal of Medicine
  • "Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology," 2022, Journal of the National Comprehensive Cancer Network
  • "NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020," 2020, Journal of the National Comprehensive Cancer Network
  • "Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology," 2022, Journal of the National Comprehensive Cancer Network

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

    Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

    Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong

  • Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Poulikos I. Poulikakos;Yogindra Persaud;Manickam Janakiraman;Xiangju Kong

  • Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

    Jessie Villanueva;Adina Vultur;John T. Lee;Rajasekharan Somasundaram

  • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

    Timothy R. Wilson;Jane Fridlyand;Yibing Yan;Elicia Penuel

Frequent Co-Authors

Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Keith T. Flaherty
Keith T. Flaherty Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Michael B. Atkins
Michael B. Atkins Georgetown University
Georgina V. Long
Georgina V. Long University of Sydney
F. Stephen Hodi
F. Stephen Hodi Harvard University
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional medical degrees, there are various online programs that can fast-track your healthcare career in the USA. Many students looking to advance quickly consider accelerated dnp programs online to earn their Doctor of Nursing Practice in less time than usual, providing strong leadership and clinical roles in nursing.

Cost is an important consideration for many. Exploring the cheapest online dnp programs can make advanced education more affordable while still maintaining high standards of learning.

For those just starting in the field, lpn online programs offer a flexible path to becoming a Licensed Practical Nurse, a key entry-level position in the healthcare sector.

Additionally, professionals seeking specialization may benefit from the fastest post master's pmhnp programs. These allow nurses to expand their expertise in psychiatric mental health, meeting rising demand for mental health practitioners.

Best Scientists Citing Jeffrey A. Sosman

Trending Scientists